89bio, Inc. is a clinical-stage biopharmaceutical company focused on developing biologic therapies for liver and cardiometabolic diseases. The company is headquartered in San Francisco, California, with operations in Israel, and its shares trade on Nasdaq under the ticker ETNB.
Its lead investigational therapy, pegozafermin (an engineered analog of the hormone FGF21), is being evaluated for the treatment of metabolic dysfunction–associated steatohepatitis (MASH, formerly NASH) and for severe hypertriglyceridemia. 89bio’s programs leverage protein engineering to address metabolic dysregulation, fibrosis, and lipid abnormalities underlying these conditions.